920 related articles for article (PubMed ID: 25592197)
1. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
[TBL] [Abstract][Full Text] [Related]
2. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Matthaei S; Bowering K; Rohwedder K; Sugg J; Parikh S; Johnsson E;
Diabetes Obes Metab; 2015 Nov; 17(11):1075-84. PubMed ID: 26212528
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Jabbour SA; Hardy E; Sugg J; Parikh S;
Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
[TBL] [Abstract][Full Text] [Related]
4. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
5. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Rosenstock J; Hansen L; Zee P; Li Y; Cook W; Hirshberg B; Iqbal N
Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
[TBL] [Abstract][Full Text] [Related]
7. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Müller-Wieland D; Kellerer M; Cypryk K; Skripova D; Rohwedder K; Johnsson E; Garcia-Sanchez R; Kurlyandskaya R; Sjöström CD; Jacob S; Seufert J; Dronamraju N; Csomós K
Diabetes Obes Metab; 2018 Nov; 20(11):2598-2607. PubMed ID: 29947099
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
Bailey CJ; Morales Villegas EC; Woo V; Tang W; Ptaszynska A; List JF
Diabet Med; 2015 Apr; 32(4):531-41. PubMed ID: 25381876
[TBL] [Abstract][Full Text] [Related]
10. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Mathieu C; Herrera Marmolejo M; González González JG; Hansen L; Chen H; Johnsson E; Garcia-Sanchez R; Iqbal N
Diabetes Obes Metab; 2016 Nov; 18(11):1134-1137. PubMed ID: 27385192
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
Vilsbøll T; Ekholm E; Johnsson E; Dronamraju N; Jabbour S; Lind M
Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
[TBL] [Abstract][Full Text] [Related]
13. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
[TBL] [Abstract][Full Text] [Related]
15. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Matthaei S; Aggarwal N; Garcia-Hernandez P; Iqbal N; Chen H; Johnsson E; Chin A; Hansen L
Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
Jabbour SA; Frías JP; Hardy E; Ahmed A; Wang H; Öhman P; Guja C
Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
Jabbour SA; Frías JP; Ahmed A; Hardy E; Choi J; Sjöström CD; Guja C
Diabetes Care; 2020 Oct; 43(10):2528-2536. PubMed ID: 32816874
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
Diabetes Care; 2015 Jul; 38(7):1218-27. PubMed ID: 25852208
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
